Core Viewpoint - The company, 加科思-B, has seen a significant stock price increase following the announcement of a strategic equity transfer agreement with 海松资本, which will enhance its focus on key oncology pipeline products [1] Group 1: Stock Performance - 加科思-B's stock rose over 7% during trading, with a current increase of 6.12%, reaching HKD 7.8, and a trading volume of HKD 23.94 million [1] Group 2: Strategic Agreement - The company signed an equity transfer agreement with 海松资本 and an industry partner, where 海松资本 will pay RMB 125 million as an initial payment and RMB 75 million as a milestone payment to acquire 80% of 加科瑞康 [1] - Following the completion of this transaction, 加科思's ownership in 加科瑞康 will decrease to 10% [1] Group 3: Strategic Focus - The transaction aligns with the company's strategy to focus on critical oncology pipeline products targeting various key cellular pathways, including KRAS, MYC, P53, and tumor immunity [1] - The proceeds from the equity transfer, after taxes and fees, will be allocated to the development, production, and commercialization of the Pan-KRAS inhibitor and other innovative oncology projects [1]
加科思-B盘中涨超7% 公司出售非核心项目 聚焦肿瘤创新药核心管线